A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029

MLA

Tareq Salous, et al. “A Phase 2 Trial of Chemotherapy plus Pembrolizumab in Patients with Advanced Non–small Cell Lung Cancer Previously Treated with a PD‐1 or PD‐L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029.” Cancer, vol. 129, Nov. 2022, pp. 264–71. EBSCOhost, https://doi.org/10.1002/cncr.34565.

APA

Tareq Salous, Nikhil A. Shukla, Sandra K. Althouse, Susan M. Perkins, Muhammad Furqan, Ticiana Leal, Anne M. Traynor, Lawrence E. Feldman, Nasser H. Hanna, & Greg A. Durm. (2022). A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non–small cell lung cancer previously treated with a PD‐1 or PD‐L1 inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029. Cancer, 129, 264–271. https://doi.org/10.1002/cncr.34565

Chicago

Tareq Salous, Nikhil A. Shukla, Sandra K. Althouse, Susan M. Perkins, Muhammad Furqan, Ticiana Leal, Anne M. Traynor, Lawrence E. Feldman, Nasser H. Hanna, and Greg A. Durm. 2022. “A Phase 2 Trial of Chemotherapy plus Pembrolizumab in Patients with Advanced Non–small Cell Lung Cancer Previously Treated with a PD‐1 or PD‐L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC‐LUN15‐029.” Cancer 129 (November): 264–71. doi:10.1002/cncr.34565.